Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.

@article{Sharif2004MolecularPO,
  title={Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.},
  author={N. Sharif and Gary W. Williams and J. Crider and Shouxi Xu and T. Davis},
  journal={Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics},
  year={2004},
  volume={20 6},
  pages={
          489-508
        }
}
  • N. Sharif, Gary W. Williams, +2 authors T. Davis
  • Published 2004
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
DP-class prostaglandins and prostaglandin analogs (collectively, prostaglandins or PGs) such as PGD2, BW245C, ZK110841, and ZK118182, lower intraocular pressure (IOP) in animal models of ocular hypertension. A new analog of ZK118182 (AL-6556; 13,14-dihydro-ZK118182) was synthesized, and the isopropyl ester of AL-6556 (AL-6598) was shown recently to lower IOP in the ocular hypertensive cynomolgus monkey model of glaucoma and in human subjects. AL-6556 and AL-6598 had an affinity (Ki) of 2.66-4… Expand
Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.
TLDR
It is concluded that AL-6598 reduces IOP by increasing uveoscleral outflow in normotensive eyes of ketamine-sedated monkeys, despite an increase in aqueous flow, different from that of PGD(2), which decreases aqueus flow, and of the selective DP receptor agonist, BW245C, which increases both outflow facility and uveOScleralOutflow in addition to decreasing aqueously flow. Expand
Prostaglandins in the eye: Function, expression, and roles in glaucoma
TLDR
The modes of action of each of the prostaglandin molecules, their expression, their role in aqueous humour production and outflow within the eye, as well as their roles as medications for the treatment of glaucoma are examined. Expand
Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility
TLDR
It appears that AL‐8810 has become the FP receptor antagonist of choice, having a sub‐micromolar in vitro potency and ≥2 log unit selectivity against most other PG receptors when tested in several cell‐ and tissue‐based functional assays. Expand
The localization of PGE2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost
TLDR
Evidence is provided to show that all PGE(2) receptor types exist in the retina of rat pups, remain functional when the retinal cells are cultured and that specific activation of EP2 receptors with butaprost can attenuate a detrimental insult caused by insufficient serum that may occur in situ by reduced trophic support. Expand
Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2 receptor agonists
TLDR
The ocular serotonergic literature pertaining to elevated IOP in patients with ocular hypertension and glaucoma, the data on ocular hypotensive serotonin-2 agonists, and their potential mechanism(s) of action at the cellular and whole-animal level are reviewed. Expand
Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018)
TLDR
There has been a growing awareness over recent years of the therapeutic use of novel derivatives as new antiglaucoma pharmaceutical products and many patents describing new compounds acting on different prostaglandin receptors, and mainly targeting EP1-4 and FP receptors, were released. Expand
Ocular Hypotensive Activity of a Non-Peptide Bradykinin B2-Receptor Antagonist (WIN-64338) In Dutch-Belt Rabbits- A Case of Poly-Pharmacology in Action
TLDR
Ocular Hypotensive Activity of a NonPeptide Bradykinin B2-Receptor Antagonist (WIN-64338) in Dutch-Belt Rabbits A Case of Poly-Pharmacology in Action. Expand
International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
TLDR
The DP2 receptor, also termed CRTH2, has little structural resemblance to DP1 and other receptors described in the original prostanoid receptor classification and is anticipated to lead to novel therapeutic entities. Expand
Regulation of [3H]D-Aspartate Release by the 5-F2t-Isoprostane and Its 5-Epimer in Isolated Bovine Retina
TLDR
The 5-F2-IsoP epimer pair, 5- F2t-I soP and 5-epi-5-F 2t- IsoP, attenuate K+-induced [3H]D-aspartate release in isolated bovine retina presumably via prostanoid receptor dependent mechanisms. Expand
Positioning prostanoids of the D and J series in the immunopathogenic scheme.
TLDR
This review highlights the collective relevance of PGD(2) and its respective synthases, receptors, and metabolites in immunopathologic responses. Expand
...
1
2
...

References

SHOWING 1-10 OF 48 REFERENCES
Studies on the ocular pharmacology of prostaglandin D2.
TLDR
Both the ocular hypotensive actions and the conjunctival pathology of PGD2 may be replicated individually by employing PGD1 analogues and metabolites by employing selective DP-receptor agonists. Expand
Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells.
  • J. Crider, N. Sharif
  • Biology, Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2001
TLDR
More than TM-3 and NPE cells apparently contain functional EP2 and EP4 prostanoid receptors positively coupled to adenylyl cyclase, indicating apparent noncompetitive antagonism profiles. Expand
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.
TLDR
Clinical studies show that travoprost 0.004% (isopropyl ester) provided intraocular pressure control superior to timolol 0.5% when used as monotherapy in patients with open-angle glaucoma or ocular hypertension, and AL-6598 0.01% provided a sustained intraocular Pressure reduction with q.i.d. application. Expand
Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans
TLDR
The results indicate that although PGD2 and BW245C are effective in reducing human IOP, their clinical usefulness as anti-glaucoma drugs may be limited by the extraocular side effects. Expand
Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats.
TLDR
The results clearly show that the DP receptors in rabbit and cat eyes are involved in intraocular pressure regulation, however, under baseline conditions DP receptor activity does not contribute to this regulation. Expand
Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit.
The mechanism underlying the intraocular pressure (IOP) lowering effect of a novel prostaglandin-related compound, (+)-isopropyl Z-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)-cyclopentyl]hept-5Expand
Effects of prostaglandin D2 and its analogues on intraocular pressure in rabbits.
TLDR
PGE2 was the strongest in causing these side effects, followed by PGF2 alpha, and PGD2 did not cause any of these responses except for some development of conjunctival hyperemia. Expand
Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes.
TLDR
It is demonstrated that PGs other than F2 alpha are potent ocular hypotensive agents in primates. Expand
The DP‐Receptor Agonist SQ27986 Raises but Does Not Lower Intraocular Pressure in Ocular Normotensive Monkeys
TLDR
The inability of SQ27986 to reduce IOP in ocular normotensive monkeys suggests that DP-receptor stimulation does not increase uveoscleral outflow or play a major role in IOP reduction by other relatively nonselective prostaglandins such as PGF2α. Expand
Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology.
  • T. Davis, N. Sharif
  • Chemistry, Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 1999
TLDR
Quantitative autoradiographic visualization of FP prostaglandin receptors was determined in postmortem human eye sections using [3H]PGF2alpha and the novel phosphor-imaging technology coupled with computerized image analysis to provide further evidence for the presence of FP receptors in human longitudinal ciliary muscle, one of the tissues involved in the intraocular pressure lowering effects of FP-class prostaglandsins. Expand
...
1
2
3
4
5
...